These results suggest that weight gain and lack of weight stability are associated with risk of endometrial cancer.

This abstract was withdrawn by the authors. Citation Format: Schoemaker MJ, Nichols HB, Wright LB, Brook MN, Jones ME, O'Brien KM, Adami H-O, Baglietto L, Bernstein L, Bertrand KA, Boutron-Ruault M-C, Chen Y, Connor AE, Dorronsoro M, Dossus L, Eliassen AH, Giles GG, Gram IT, Hankinson SE, Kaaks R, Key TJ, Kirsh VA, Kitahara CM, Koh W-P, Larsson SC, Linet MS, Ma H, Masala G, Merritt MA, Milne RL, Overvad K, Ozasa K, Palmer JR, Riboli E, Rohan TE, Sadakane A, Sund M, Tamimi RM, Trichopoulou A, Ursin G, Van Gils CH, Visvanathan K, Weiderpass E, Willett WC, Wolk A, Yuan J-M, Zeleniuch-Jacquotte A, Sandler DP, Swerdlow AJ. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-08-01.

consideration of prevention options; decision-making processes and networks, and psychosocial well-being. Transcribed data are analyzed with NVivo 10, using grounded theory methods. Results: Prevention decision making by women who have had close contact with the cancer diagnosis and treatment of a loved one (most often a mother or grandmother, but sometimes a sister, cousin, or close friend) is importantly influenced by these experiences. The process of deciding whether and when to undertake prophylactic mastectomy or oophorectomy, chemoprevention, enhanced surveillance, and/or genetic testing is substantially different in women who have and have not had close personal experience with the cancer of a loved one. Women who have experienced the deaths of one or more loved ones express strong motivation and willingness to undertake definitive interventions; most often this means prophylactic surgery, but this can also include chemoprevention. These women often feel that they are likely to be diagnosed with breast cancer eventually, and seek decisive methods to avoid what they perceive as a life-threatening diagnosis. Women whose loved ones have survived and thrived after a cancer diagnosis are more oriented toward careful surveillance through screening tests and physician checks. These women usually see breast cancer as a challenge they may have to deal with in the future, and they are motivated to set the stage for treatment success by establishing ongoing relationships with highly competent healthcare providers, and by being diagnosed as early as possible. Conclusions: Cancer care has strong effects beyond the cancer patient herself, affecting the decisionmaking processes and the prevention-related decisions of loved ones as well. Future prevention research for women at elevated risk should consider how their prior experiences with the cancer of friends or family members structure women's expectations of cancer risk, prevention, and outcomes. Active Tobacco Smoke and Environmental Tobacco Smoke Exposure During Potential Biological Windows of Susceptibility in Relation to Breast CancerWhite AJ, D'Aloisio AA, Nichols HB, DeRoo LA, Sandler DP Purpose: Our objective was to prospectively examine active smoking and environmental tobacco smoke (ETS) in relation to breast cancer risk, with a focus on exposures during potential windows of susceptibility. Methods: Sister Study cohort participants (n ¼ 50,884) were enrolled between 2003 and 2009 and were followed for a breast cancer diagnosis. Women ages 35-74 in the United States and Puerto Rico were eligible if they had a sister who had been diagnosed with breast cancer. Study participants completed extensive telephone and paper questionnaires including information on established breast cancer risk factors as well as active smoking history and exposure to ETS while in utero and during childhood and adult years. Cox regression analysis was used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (95% CIs) for invasive breast cancer incidence associated wi...

provide valuable insight about potential vaccine impact. Methods: We examined trends in the incidence of invasive cervical cancer by race and histology among young women (15-24 years and 25-34 years) during the prevaccine era (2000-2006) and the vaccine era (2007-2013). Data were from the Surveillance, Epidemiology, and End Results (SEER) Program, including 18 SEER registry areas (Hurricane Katrina impacted Louisiana population excluded). Incidence rates (per 1,000,000) were age-adjusted to the 2010 US standard population by the direct method, using SEER Ã Stat software. Confidence intervals were calculated using the Tiwari method. Joinpoint regression modeling was used to compare the difference in the trends between the prevaccine era and the vaccine era. Results: Cervical cancer incidence among young women 15-24 years of age was stable

Background: Chemotherapy can damage the ovaries and cause amenorrhea, a surrogate for infertility. Young women often wish to understand and minimize their risk of chemotherapy-related amenorrhea (CRA). However, the incidence of CRA with regimens that do not include either an anthracycline or cyclophosphamide is poorly studied. For patients with HER-2 positive disease, these anthracycline and cyclophosphamide-sparing regimens (e.g., docetaxel-carboplatin) are common (in combination with Her-2 directed therapy) in both the neoadjuvant and adjuvant settings. Methods: Women diagnosed with breast cancer under age 50 and within the past 10 years were recruited through a Dr. Susan Love Research Foundation Army of Women e-mail blast. Those who provided their contact information were mailed a consent form and medical record authorization form. Participants then received a web-based survey that inquired about receipt of and type of chemotherapy (including date of last dose) and date of last menstrual period (LMP). Patient-reported LMP was compared to date of final chemotherapy dose to determine if the LMP occurred before (defined as “CRA”) or after the last chemotherapy dose. When available, medical record data was used in place of survey data regarding type of chemotherapy used. Exclusion criteria included: LMP prior to diagnosis date, receipt of multiple chemotherapy regimens or no chemotherapy regimens, receipt of ovarian suppression medications (which interfere with interpretation of menstrual data), surgical menopause prior to or at the same time as diagnosis, a cancer diagnosis more than 10 years prior, incomplete menstrual data on the survey, report of an unknown chemotherapy regimen, and no date available for the last chemotherapy dose without an LMP within a month prior to survey completion. Fisher Exact test was used to compare CRA rates between regimens. Rates after two anthracycline-sparing regimens (taxane/cyclophosphamide; taxane/carboplatin) were compared to rates after anthracycline/cyclophosphamide/taxane. Results: 273 women consented to participate in this study, 258 of whom filled out the web survey. 151 of them were eligible for this analysis with a median age at diagnosis of 41 (range 24-49) and a median time from last chemotherapy dose to survey of 62.5 months (range 2-138). CRA occurred in 51.2% of the 86 participants who received an anthracycline, cyclophosphamide, and a taxane, in 41.9% of the 43 participants who received only a taxane and cyclophosphamide (p=0.35), and in 13.3% of the 15 participants who received carboplatin with a taxane (p=0.01). When the 11 patients who were <12 months since last chemotherapy were excluded, CRA rates changed minimally. Age did not differ by regimen, but median time since chemotherapy was shorter in the taxane/carboplatin group (35 months vs. 68 months). Trastuzumab with or without pertuzumab was administered in 100% of patients who received carboplatin/taxane, in 23.3% of patients who received taxane and cyclophosphamide, and in 22.1% of patients who received anthracycline/cyclophosphamide/taxane. Conclusions: This study suggests that carboplatin/taxane may be substantially less gonadotoxic than cyclophosphamide-based (neo)adjuvant regimens. Further research is necessary to confirm these findings. Citation Format: Gast KC, Cathcart-Rake EJ, Norman A, Eshragi L, Obidegwu N, Yost K, Nichols HB, Rosenberg S, Su HI, Stewart E, Couch F, Vachon C, Ruddy KJ. Regimen-specific rates of chemotherapy-related amenorrhea in breast cancer survivors [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-12-10.